

Influence of Baseline Characteristics on Smoking Cessation in MDD: A Study of Behavioral and Pharmacological Treatment Effects

Yingxi Kong

Abstract

Background: People with Major Depressive Disorder (MDD) are more likely to engage in tobacco use. However, most smoking cessation clinical trials had excluded this group from the enrollment, limiting available information to support smoking cessation for this group. This study, collaborating with Dr. George Papandonatos, aims to evaluate behavioral and pharmacological treatment for smoking cessation in adults with MDD to identify baseline characteristics that may moderate the behavioral treatment or predict smoking cessation outcome.

Methods: In a 2×2 factorial, randomized, placebo-controlled trial, 300 adult smokers with current or past MDD were randomly assigned to either Behavioral Activation for Smoking Cessation (BASC) or standard treatment (ST), combined with either varenicline or placebo. Participants' demographic characteristics, smoking behavior, mental health measurement, and the abstinence outcome at the week 27 follow-up were collected. Lasso regression was employed to identify significant baseline characteristics and potential interaction effects with treatment, controlling for both behavioral and pharmacotherapy assignments.

Results: Findings suggest that as predictors, controlling for treatment groups and other factors, having higher nicotine metabolism ratio and identifying as Non-Hispanic White were associated with higher likelihood of abstinence, while higher nicotine dependence score, higher pleasurable events scale score, and current MDD experience were associated with lower odds of abstinence. Moreover, income, menthol cigarette users indicators, and MDD status serve as moderators of the behavioral treatment effect on the end-of-treatment (EOT) abstinence.

Conclusion: This study provides insights into how smoking cessation treatment outcomes among adults with MDD interact with baseline characteristics, identifying demographic factors, nicotine dependence, and MDD status as key predictors and moderators. However, variation in treatment adherence and several underrepresented groups could have influenced the estimate of treatment effect. Further research should explore strategies to improve engagement and broaden data collection to achieve better representation of these groups, enhancing the accuracy and generalizability of the findings.

Introduction

Major Depressive Disorder (MDD) has been one of the most prevalent mental health disorders in the world, with rates that have continued to rise, particularly during the COVID-19 pandemic¹. Individuals with MDD are not only at risk for a range of adverse health outcomes but are also more likely to engage in harmful health behaviors, including tobacco use. The rate of smoking among individuals with MDD is 2–3 times higher than in the general population². However, most smoking cessation clinical trials have excluded this important group from the trial enrollment³, thereby limiting available information and recommendations to support smoking cessation for this group.

A recent randomized, placebo-controlled trial led by Dr. George Papandonatos evaluated the efficacy and safety of combining behavioral and pharmacological treatment for smoking cessation among individuals with current or past MDD. The study involved 300 participants and employed a 2×2 factorial design to compare

Behavioral Activation for Smoking Cessation (BASC) with standard treatment (ST), and varenicline with placebo. BASC, a behavioral intervention designed to enhance engagement in rewarding activities and reduce avoidance behavior, was paired with varenicline, a pharmacotherapy shown to reduce cravings and mitigate nicotine’s rewarding effects. The results indicated that while varenicline significantly improved abstinence rates compared to placebo, BASC did not outperform ST, suggesting that while pharmacotherapy may provide substantial benefits for smokers with MDD, the behavioral component of cessation treatment may require further refinement.

Collaborating with Dr. George Papandonatos, this study aims to investigate the role of baseline characteristics as potential moderators of the effectiveness of behavioral treatment on end-of-treatment (EOT) abstinence outcomes. Furthermore, we aim to assess these baseline characteristics as predictors of abstinence, while controlling for both behavioral treatment and pharmacotherapy. By identifying factors that may influence the efficacy of cessation interventions, this analysis would contribute to inform targeted treatment strategies to enhance smoking cessation outcomes among individuals with MDD.

Methods

Our sample population consists of 300 adult smokers with or previously with MDD. Patients were randomly assigned to either behavioral activation for smoking cessation (BASC) or standard behavioral treatment (ST) and either varenicline or placebo groups. That is, participants were assigned to four distinct intervention groups, including `ST + placebo`, `ST + varenicline`, `BASC + placebo`, and `BASC + varenicline`. Randomization was stratified by clinical site, sex, and level of depressive symptoms to ensure balanced representation across these factors.

Follow-up data was collected at week 27 to assess smoking cessation outcomes, along with relevant baseline characteristics. Key variables include smoking abstinence status, demographic characteristics (sex, age, income, and education), smoking behaviors (number of cigarettes per day, time to first cigarette after getting up, and nicotine dependence score), and psychiatric measures (MDD status, anhedonia score, other diagnoses, and antidepressant usage).

Data Preprocessing

To prepare dataset for analysis, we firstly converted all categorical variables into factors. For socioeconomic factors, income and education, we recoded levels to improve readability and interpretability. In addition, we combined race and ethnicity indicators into a single race variable with categories including Black, Hispanic, Non-Hispanic White, Mixed Race, and Unknown.

The dataset contains varying levels of missingness across several variables as presented in **Table 1**. Nicotine Metabolism Ratio (NMR) has the highest missing rate, with 7% of observations missing. The FTCD score at baseline (`ftcd_score`) has the lowest missing rate, 0.33%, with only one patient missing this information. Given our limited sample size, we prefer to retain as many observations as possible for our analysis. Therefore, to address the missingness, we applied a multiple imputation approach using the `mice()` function from the `mice` package in R, generating five imputed datasets to provide plausible values for all missing entries before proceeding to the primary analysis.

Table 1: Summary of Missing Data Patterns Across Variables

Variable	Missing Count	Missing Percentage
NMR	21	7 %
crv_total_pq1	18	6 %
readiness	17	5.67 %
inc	3	1 %
shaps_score_pq1	3	1 %
Only.Menthol	2	0.67 %
ftcd_score	1	0.33 %


Data Exploration and Transformation

To explore potential interactions between baseline characteristics and treatment assignment on EOT abstinence, we examined the distribution of each baseline variable across treatment groups and abstinence outcomes.

For categorical variables, bar charts show patterns across treatment groups and abstinence groups in **Figure 1** and **Figure 2**. Income in **Figure 1** exhibits different distributions among groups and abstinence outcomes. Within each treatment group, different income levels show various proportions of abstinence, suggesting that income level may be a potential predictor of treatment effect on abstinence.

In the **BASC + placebo** group, most participants with incomes lower than \$20,000 did not achieve abstinence at the week 27 follow-up, while nearly half of those in the **ST + placebo** group with similar income level achieved abstinence. In addition, people with income ranging from \$35,001 to \$50,000 are more likely to quit smoking at the week 27 follow-up in the **BASC + placebo** group while most participants with this income level assigned to the **ST + placebo** group did not achieve abstinence. Similar variations in abstinence outcomes within income levels were observed when comparing the two behavioral treatments combined with varenicline, indicating that income level might be a potential moderator of the behavioral treatment effectiveness on the EOT abstinence among people with MDD.

Figure 1: Baseline Characteristics by Abstinence Status and Treatment Group (Categorical 1)



Similarly, as shown in **Figure 1**, education level appears to impact abstinence rates across treatment groups. Within each treatment group, participants with different education levels demonstrate varying abstinence rates at follow-up. For example, observing the **BASC + placebo** group, college graduated participants are more likely to achieve abstinence at the follow up compared to those with lower education levels, suggesting that income level may be a predictor of treatment effect on abstinence.

Additionally, comparing the two behavioral treatments with varenicline, college graduates in the **ST + varenicline** group show higher abstinence rates at week 27 than those in the **BASC + varenicline** group. Also, patients with a high school diploma or GED exhibit a higher likelihood of smoking cessation with BASC while their abstinence rate becomes much lower with ST. These findings suggest that education levels moderate the effects of behavioral treatment on EOT abstinence among individuals with MDD.


Race and the indicator of exclusive mentholated cigarette users (**Only.Menthol**) also show differences in

distribution across treatment groups and outcome values, as shown in Figure 2. For example, in the ST + placebo, BASC + placebo, and BASC + varenicline groups, non-Hispanic White participants are more likely to stop smoking compared to other racial groups. This indicates that race might be a predictor of the treatment effect on EOT abstinence for people with MDD.

Additionally, comparing the two behavioral treatments with placebo, Hispanic participants with ST are more likely to achieve smoking cessation while this pattern reverses when they were assigned to BASC. Moreover, comparing the two varenicline groups, black people with BASC show less likelihood of stopping smoking while they show a larger abstinence rate in the ST group.

Similar pattern observed for the indicator of exclusive mentholated cigarette users (`Only.Menthol`). In the two varenicline groups, mentholated cigarette users (`Only.Menthol` = 1) with ST are more likely to achieve abstinence while these users with BASC exhibit much lower abstinence rate at week 27 follow-up. These findings suggest that race and the indicator of exclusive mentholated cigarette users could be potential predictors or moderators of the treatment effects on the EOT abstinence for people with MDD.

Figure 2: Baseline Characteristics by Abstinence Status and Treatment Group (Categorical 2)



We also examine the distribution of continuous variables by treatment groups and outcome status, as shown in Figure 3 and Figure 4. Among continuous variables, age (`age_ps`), FTCD score, NMR, and BDI score (`bdi_score_W00`) exhibited differences in distribution across treatment groups and abstinence status at the week 27 follow-up.

Seeing Figure 3, the abstinence rate varies with age within the same treatment group, suggesting age as a predictor of treatment effect on EOT abstinence. Moreover, in the two placebo groups, younger participants in the BASC + placebo group show higher abstinence rate while this group of individuals exhibits lower abstinence rate in the ST + placebo group. Within the varenicline groups, middle-aged participants in ST + varenicline demonstrate significantly higher abstinence rates than middle-aged participants in BASC + varenicline.

The FTCD score also appears to influence abstinence outcomes, with abstinence rates changing as FTCD scores vary. Moreover, participants with higher FTCD score in the ST + placebo group show significantly higher likelihood to continue smoking compared to those in the BASC + placebo group. Moreover, participants with FTCD score around 5 in the ST + varenicline group show higher abstinence rate compared to those

in the **BASC + varenicline** group. These findings suggest potential interactions between age and behavioral treatment, as well as FTCD score-treatment and treatment. Age and FTCD score might serve as predictors and moderators of the treatment effect on the EOT abstinence.

Figure 3: Baseline Characteristics by Abstinence Status and Treatment Group (Continuous 1)





Figure 4: Baseline Characteristics by Abstinence Status and Treatment Group (Continuous 2)




Seeing Figure 4, the distribution of NMR is right skewed towards participants with higher values across

all treatment groups. In the placebo groups, participants with lower NMR are more likely to quit smoking at the week 27 follow-up while this gap is less pronounced in the varenicline groups. Within the **BASC + placebo** group, there is a huge gap in abstinence rate between participants with NMRs ranging from 0.3 to 0.5. Moreover, comparing the varenicline groups, participants with NMRs between 0.3 and 0.7 show higher abstinence rate in the **ST + varenicline** group but lower abstinence rate in the **BASC + varenicline** group.

For the BDI score (measure of depression), which reflects depressive symptom severity, distinct patterns also emerge. In the placebo groups, participants in the ST group with lower BDI scores (indicating less severe depressive symptoms) are more likely to stop smoking, while those with moderate BDI scores show lower abstinence rates. However, in the BASC group, participants show a more uniform distribution regardless of their depressive severity. The same pattern was observed when we compared the two varenicline groups, suggesting a complex interacting relationship between BDI score and the combination of behavioral and pharmacological treatments. These findings suggest that both NMR and BDI scores may interact with behavioral treatment types, influencing smoking cessation outcomes and potentially serving as moderators of treatment effects.

Additionally, examining the correlation among continuous variables shown in **Figure 5**, we observed that most variables show low to moderate correlations with each other, with both positive and negative relationships present.

Figure 5: Correlation Plot among Environmental Condition Characteristics



To address skewness in several variables, we applied specific transformations based on the distributional characteristics of each variable, with transformations performed after the imputation step. Among the continuous variables, pleasurable events scale of substitute reinforcers (**hedonsum_n_pq1**), pleasurable events scale of complementary reinforcers (**hedonsum_y_pq1**), measure of anhedonia (**shaps_score_pq1**), and NMR exhibit right-skewed distributions. **Table 2** summarizes the skewness value of these variables before and after transformation.

For the two pleasurable event scale variables, **hedonsum_n_pq1** and **hedonsum_y_pq1**, we applied a square root transformation to reduce high positive skewness values (1.34 and 1.39, respectively). This transformation brought their skewness close to zero (-0.06 and 0.06, respectively), resulting in more symmetric distributions.

Additionally, given that **shaps_score_pq1** had nearly 50% zero entries and a high positive skewness (1.71), we explored several transformations, including log, square root, and inverse hyperbolic sine (**asinh()**). The inverse hyperbolic sine transformation produced the lowest skewness (0.52), making it the most suitable

choice for this variable.

Finally, we applied a log transformation on NMR which presents the highest skewness value before transformation (1.92). The log transformation successfully reduced the skewness to a nearly symmetric value.

Table 2: Variable Transformation on Skewness

Variable	Transformation	Skewness before Transformation	Skewness after Transformation
hedonsum_n_pq1	Square Root Transformation	1.338843	-0.0591728
hedonsum_y_pq1	Square Root Transformation	1.391398	0.0620129
shaps_score_pq1	Inverse Hyperbolic Sine Transformation	1.707230	0.5217093
NMR	Log Transformation	1.915358	-0.2241582

To analyze the impact of behavioral treatment on end-of-treatment abstinence and examine the moderating role of baseline characteristics, we selected Lasso regression as our primary model. Lasso was chosen for its ability to perform both variable selection and regularization, making it particularly suited for our study, which involves numerous baseline predictors and interaction terms. By applying an L1 penalty, Lasso shrinks less relevant coefficients to zero, effectively selecting a subset of the most influential predictors and interactions.

Results

Before conducting the primary analysis, we performed exploratory data analysis (EDA) to examine baseline characteristics, assess data distributions, and identify potential relationships within the dataset.

Table 3 presents an overall summary of statistics of patients’ baseline characteristics by their behavioral and pharmacological treatment assignment. Since our study is a 2×2 , factorial, randomized, placebo-controlled trial, patients are randomly assigned to either behavioral activation for smoking cessation group (BASC) or standard behavioral treatment group (ST) and either varenicline or placebo blister pack. Patients can be categorized into four treatment arm groups: BASC + placebo, BASC + varenicline, ST + placebo, and ST + varenicline. From **Table 3**, the two placebo groups both have 68 observations while the two varenicline groups have 83 and 81 observations, respectively.

Most variables are evenly distributed across the four treatment arms, which reflects successful randomization in this factorial trial. However, a few key factors, such as socioeconomic indicators (income and education) and specific mental health variables (MDD status, DSM-5 diagnoses), exhibit slight variations that may influence outcomes. Notably, treatment arms with varenicline show higher abstinence rates than placebo groups, suggesting the potential efficacy of this pharmacotherapy in combination with behavioral interventions. While many baseline characteristics are evenly distributed across groups, some may still function as moderators, potentially interacting with treatment assignment to affect abstinence success. In addition, only one observation falls into the Grade School level in the education variable. To ensure the appropriate representation of categories, we combined the grade school level with the next level, some high school, during the regression analysis. This adjustment ensures sufficient sample sizes across categories when we split the data.

Table 3: Participant Characteristics by Treatment Arm

Characteristic	Behavioral and Pharmacological Treatment Assignment				Overall, N = 300
	ST + placebo, N = 68	BASC + placebo, N = 68	BASC + varenicline, N = 83	ST + varenicline, N = 81	
Smoking abstinence	8 (12%)	4 (5.9%)	26 (31%)	26 (32%)	64 (21%)
Age	50 (11)	51 (14)	50 (13)	49 (13)	50 (13)
Sex					
Male	29 (43%)	30 (44%)	39 (47%)	37 (46%)	135 (45%)
Female	39 (57%)	38 (56%)	44 (53%)	44 (54%)	165 (55%)
Income					
Less than \$20,000	26 (38%)	25 (37%)	30 (37%)	29 (36%)	110 (37%)

Table 3: Participant Characteristics by Treatment Arm (*continued*)

Characteristic	Behavioral and Pharmacological Treatment Assignment				
	ST + placebo, N = 68	BASC + placebo, N = 68	BASC + varenicline, N = 83	ST + varenicline, N = 81	Overall, N = 300
\$20,000-35,000	14 (21%)	16 (24%)	17 (21%)	21 (26%)	68 (23%)
\$35,001-50,000	14 (21%)	8 (12%)	13 (16%)	11 (14%)	46 (15%)
\$50,001-75,000	8 (12%)	12 (18%)	12 (15%)	6 (7.5%)	38 (13%)
More than \$75,000	6 (8.8%)	6 (9.0%)	10 (12%)	13 (16%)	35 (12%)
Missing	0	1	1	1	3
Education					
Some high school & Grade School	2 (2.9%)	4 (5.9%)	7 (8.4%)	4 (4.9%)	17 (5.7%)
High school graduate or GED	11 (16%)	23 (34%)	15 (18%)	27 (33%)	76 (25%)
Some college/technical school	38 (56%)	22 (32%)	32 (39%)	24 (30%)	116 (39%)
College graduate	17 (25%)	19 (28%)	29 (35%)	26 (32%)	91 (30%)
FTCD score	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)
Missing	1	0	0	0	1
Smoking within 5 mins of waking up	35 (51%)	32 (47%)	33 (40%)	38 (47%)	138 (46%)
BDI score	18 (11)	19 (12)	18 (11)	20 (12)	19 (11)
Cigarettes smoked per day	15 (7)	16 (9)	16 (9)	14 (7)	15 (8)
Cigarette reward value	7 (4)	7 (4)	7 (4)	7 (3)	7 (4)
Missing	8	1	3	6	18
Pleasurable events (substitute reinforcers)	21 (20)	23 (20)	23 (19)	23 (19)	23 (20)
Pleasurable events (complementary reinforcers)	27 (20)	28 (22)	22 (17)	25 (19)	25 (19)
Anhedonia	3 (3)	2 (3)	2 (3)	2 (3)	2 (3)
Missing	1	2	0	0	3
Other lifetime DSM-5 diagnosis	28 (41%)	35 (51%)	30 (36%)	40 (49%)	133 (44%)
Taking antidepressant Current vs. past MDD	15 (22%)	28 (41%)	24 (29%)	15 (19%)	82 (27%)
Past MDD	37 (54%)	36 (53%)	43 (52%)	37 (46%)	153 (51%)
Current MDD	31 (46%)	32 (47%)	40 (48%)	44 (54%)	147 (49%)
Nicotine metabolism ratio	0.37 (0.27)	0.34 (0.18)	0.38 (0.25)	0.36 (0.21)	0.36 (0.23)
Missing	2	7	3	9	21
Exclusive mentholated cigarette user	43 (64%)	40 (59%)	48 (59%)	47 (58%)	178 (60%)
Missing	1	0	1	0	2
Readiness to quit smoking	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)
Missing	4	4	5	4	17
Race					
Black	40 (59%)	36 (53%)	36 (43%)	43 (53%)	155 (52%)
Hispanic	4 (5.9%)	4 (5.9%)	3 (3.6%)	5 (6.2%)	16 (5.3%)
Mixed Race	0 (0%)	1 (1.5%)	1 (1.2%)	0 (0%)	2 (0.7%)
Non-Hispanic White	22 (32%)	24 (35%)	34 (41%)	25 (31%)	105 (35%)
Unknown	2 (2.9%)	3 (4.4%)	9 (11%)	8 (9.9%)	22 (7.3%)

¹ Mean (SD) for continuous; n (%) for categorical

As mentioned earlier, we performed multiple imputation using the `mice()` function to generate five different imputed data to address missingness. We then applied transformations listed in Table 2 to the corresponding skewed variables in each imputed dataset. Each imputed dataset was then split into a 70% training set and a 30% test set, stratified by treatment group using the `createDataPartition()` function in the `caret` package.

Lasso regression was conducted on each training set using `cv.glmnet()` with a design matrix that included all baseline characteristics and their interactions with the behavioral and pharmacological treatment, respectively. To ensure consistent treatment group distribution across each cross-validation fold in lasso regression, we created custom fold assignments by treatment level and specified these assignments through the `foldid`

argument in `cv.glmnet()`.

During cross-validation, we identified the optimal regularization parameter, `lambda.min`, which minimized the cross-validated error, and extracted the coefficient estimates for each lasso model at this optimal lambda value. Finally, we averaged the coefficient estimates from all five Lasso models to obtain the final pooled estimates, presented in Table 4.

Table 4: Lasso Model Coefficient Estimate

	Variable	Imputation 1	Imputation 2	Imputation 3	Imputation 4	Imputation 5
1	(Intercept)	-0.9858368	-0.8559755	-1.1638498	-0.9061058	-1.0172281
8	ftcd_score	-0.1198026	-0.1160073	-0.1207733	-0.1194138	-0.1323784
9	hedonsum_n_pq1	0.0000000	0.0000000	0.0000000	0.0000000	-0.0093333
10	mde_curr1	-0.1940984	-0.1922978	-0.2090639	-0.2033876	-0.2283386
11	NMR	0.2494848	0.3616764	0.1091799	0.3070181	0.1543496
13	raceNon-Hispanic White	0.2991766	0.2796795	0.3613284	0.2622257	0.4057589
3	BA1:inc\$35,001- 50,000	0.0000000	0.0000000	0.0000000	0.0000000	0.0621926
4	BA1:Only.Menthol1	-0.3694831	-0.4048011	-0.3137973	-0.3862525	-0.4467786
5	BA1:raceNon- Hispanic White	0.0000000	0.0023216	0.0000000	0.0101141	0.0176939
2	age_ps:Var1	0.0162105	0.0168513	0.0164146	0.0156714	0.0201370
6	crv_total_pq1:Var1	0.0318846	0.0254871	0.0274194	0.0346775	0.0025389
7	eduHigh school graduate or GED:Var1	0.0304747	0.0259790	0.0509466	0.0211769	0.0997030
12	raceMixed Race:Var1	0.8216995	0.7832045	0.8426509	0.8111792	1.0186898
14	sex_ps2:Var1	0.0663181	0.0558703	0.0898271	0.0702265	0.1108091

Table 5: Lasso Model Coefficient Estimate

Variable	Estimate	Exponential Estimate
(Intercept)	-0.9857992	0.3731409
ftcd_score	-0.1216751	0.8854360
hedonsum_n_pq1	-0.0018667	0.9981351
mde_curr1	-0.2054373	0.8142912
NMR	0.2363417	1.2666071
raceNon-Hispanic White	0.3216338	1.3793796
BA1:inc\$35,001-50,000	0.0124385	1.0125162
BA1:Only.Menthol1	-0.3842225	0.6809799
BA1:raceNon-Hispanic White	0.0060259	1.0060441
crv_total_pq1:Var1	0.0244015	1.0247016
eduHigh school graduate or GED:Var1	0.0456560	1.0467143
raceMixed Race:Var1	0.8554848	2.3525146
sex_ps2:Var1	0.0786102	1.0817826
age_ps:Var1	0.0170570	1.0172033

Observing the main effects in Table 4, we find that the FTCD score has a coefficient of -0.1217, suggesting that each one-unit increase in FTCD score decreases the odds of abstinence for people with MDD by approximately 11.46%, indicating that higher nicotine dependence may reduce abstinence likelihood, holding other factors constant. Similarly, the square root transformed pleasurable events scale of substitute reinforcers, `hedonsum_n_pq1`, and the MDD status indicator (`mde_curr1`) display negative coefficient estimates, suggesting the negative association between higher pleasurable events scale and current MDD experience and the odds of smoking abstinence.

Moreover, the log-transformed Nicotine Metabolism Ratio (NMR) and the race variable (Non-Hispanic White group) both present a positive association with the smoking cessation outcome among people with MDD, controlling for other covariates. Notably, the interaction term between BASC treatment and race exhibits

significant estimate as well, suggesting that Non-Hispanic White participants using BASC would experience a small additional increase in abstinence odds. Thus, the NMR and race variable not only functions as predictors but also as moderators.

This is same for the indicator of exclusive mentholated cigarette user, `Only.Menthol`, and the income characteristics, `inc`. The interaction term between BASC treatment and `Only.Menthol` displays an estimate of -0.3842, suggesting that for MDD people receiving the BASC treatment, those who are mentholated cigarette user would have a 31.81% of decrease in the odds of abstinence compared to those who are not mentholated cigarette user. Additionally, the interaction term between BASC treatment and income (\$35,001- 50,000) has an estimate of 0.0124. This suggests that for MDD people receiving the BASC treatment, those who have income ranging from \$35,000 to \$50,000 would experience approximately a 1.25% increase in the odds of abstinence compared to individuals with different income levels.

The model also has several interaction term with the indicator of varenicline treatment (`Var`) which identify potential moderators for the pharmacological treatment on the EOT abstinence for people with MDD. Specifically, cigarette reward value (`crv_total_pq1`), education level (level: high school graduate or GED), race (level: mixed race), sex, and age serve as potential moderators. These interactions suggest that the effectiveness of varenicline may vary depending on these baseline characteristics, highlighting the nuanced impact of pharmacological treatment across different demographic and behavioral profiles.

Figure 6: ROC Curves for Train and Test Data





Figure 7: Calibration Plot Comparison



We also examine the model’s performance using ROC and calibration plots shown in **Figure 6** and **Figure 7**. The prediction values for the train and test sets are calculated using the long format of train and test sets from the five imputed datasets, respectively. Observing **Figure 6**, the ROC curves indicate that our model effectively distinguishes between positive and negative classes. The train set has an AUC of 0.81 while the test set has an AUC of 0.75. Although there is a slight drop in AUC on the test set, the model still shows great discriminative power on unseen data.

Moreover, observing **Figure 7**, the calibration plot for the training set shows that the model is well-calibrated with lower probability predictions, with points distributed around the diagonal line which indicates the alignment between the predictions and observed values. However, as probabilities increase, slight deviations appear. The test set calibration plot shows more pronounced deviations from the diagonal line. This suggests that while the model’s predictions are reasonably aligned with actual outcomes for the training data, calibration issues are more substantial in the test set, which needs further investigation.

Discussion

Collaborating with the study of smoking cessation for people with MDD led by Dr. George Papandonatos, this study aims to further investigate potential moderators of behavioral treatment (BASC vs. ST) on the EOT abstinence for this group of people and dedicates to identify baseline characteristics as predictors of abstinence, controlling for behavioral and pharmacotherapy treatment. Lasso regression is chosen to perform variable selection that helps to focus on the most influential baseline characteristics and their interaction terms, balancing predictivity with interpretability.

Control for treatment and other factors, as predictors, higher nicotine dependence (higher FTCD score), higher pleasurable events scale score, and current MDD status both associate with lower likelihood of abstinence. Conversely, having faster nicotine metabolism (higher NMR in log scale) was associated with higher odds of abstinence, adjusting for treatment and other factors.

Additionally, race emerged as both a predictor and moderator, with Non-Hispanic White participants showing higher odds of abstinence and a greater benefit from BASC compared to other racial groups. Menthol cigarette use and income level also moderated the effects of BASC, with menthol users experiencing lower abstinence odds and individuals with incomes between \$35,001 and \$50,000 benefiting more from BASC. Furthermore, significant interaction terms with varenicline suggest that the efficacy of pharmacotherapy varies by factors like cigarette reward value, education, race, sex, and age.

The model evaluation using ROC and calibration plots reveals our model’s strong discriminative power but raises slight concern regarding calibration on the test set which needs further investigation.

As noted in the original paper, a limitation of this study is the low adherence to both behavioral treatment and pharmacotherapy, particular in the BASC-only group. The use of an ITT approach under this scenario might lead to an underestimation of treatment effects due to low adherence. An additional limitation of our analysis is that, although our sample provides a diverse phase of patients with MDD, certain levels within some categorical variables have limited sample sizes. For example, as shown in **Table 3**, only one observation falls within the “Grade school” category for education. This limited representation may reduce the statistical power and limit the generalizability of our study.

Further research could explore strategies to enhance engagement and adherence and expand data collection to achieve more balanced representation of those underrepresented groups to improve the accuracy and generalizability of our model. Additionally, a future direction would be to apply a multilevel modeling approach which allows for the analysis of time-varying and group-level predictors, such as provider expertise or site-specific support. This method would allow us to assess how these factors interact with individual characteristics to impact abstinence outcome.

Reference

1. Santomauro, D. F., Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., Vos, T., Whiteford, H., Ferrari, A. J., Charlson, F. J., et al. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *The Lancet*, *398*(10312), 1700–1712.
2. Weinberger, A. H., Chaiton, M. O., Zhu, J., Wall, M. M., Hasin, D. S., & Goodwin, R. D. (2020). Trends in the prevalence of current, daily, and nondaily cigarette smoking and quit ratios by depression status in the u.s.: 2005–2017. *American Journal of Preventive Medicine*, *58*(5), 691–698.
3. Hitsman, B., Papandonatos, G. D., McChargue, D. E., & al., et. (2013). Past major depression and smoking cessation outcome: A systematic review and meta-analysis update. *Addiction*, *108*(2), 294–306.